Brief: Prothena Announces That Novo Nordisk Will Advance Coramitug Into Phase 3 Development
06/08/2025 15:08
Aug 6 (Reuters) - Prothena Corporation PLC PRTA.O: PROTHENA ANNOUNCES THAT NOVO NORDISK WILL ADVANCE CORAMITUG (FORMERLY PRX004) INTO PHASE 3 DEVELOPMENT FOR ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY PROTHENA CORPORATION: UNDER AGREEMENT, CO IS ELIGIBLE TO RECEIVE UP TO $1.2 BILLION DOLLARS UPON ACHIEVEMENT OF CLINICAL DEVELOPMENT & SALES MILESTONES Source text: ID:nBw6ylMXVa Further company coverage: PRTA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prothena
See all newsProthena Corporation PLC reports results for the quarter ended June 30 - Earnings Summary
Biotech firm Prothena's Q2 net loss narrows on lower expenses
Brief: Prothena Q2 Net Income USD -18.583 Million
Prothena Corporation PLC expected to post a loss of 39 cents a share - Earnings Preview
Prothena posts Q1 revenue surge fueled by $50 million Novo Nordisk milestone payment